RxDoctor Payments Data

Farrukh Bhatti, MD

Psychiatry · Ft Worth, TXNPI 1457399842

Payments from drug & device makers

$2,723in general payments, 2019–2025

Across 158 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$708
  • Vanda Pharmaceuticals Inc.$356
  • Indivior Inc.$340
  • Johnson & Johnson$331
  • Alkermes, Inc.$199
  • Teva Pharmaceuticals USA, Inc.$199
  • plus $589 from 5 others

What the payments were for

  • Food & beverage$2,67698%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,723 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$12,006
Medicare patients
31
Services billed
118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate27$87,049
Lurasidone Hcl18$11,005
Clozapine30$5,665
Oxcarbazepine83$4,711
Aripiprazole88$3,348
Hydroxyzine Hcl106$3,033
Duloxetine Hcl95$2,013
Olanzapine65$1,905
Divalproex Sodium ErDivalproex Sodium36$1,808
Quetiapine Fumarate99$1,698
Naltrexone Hcl15$1,334
Prazosin Hcl33$1,254
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl19$1,242
Benztropine Mesylate93$1,205
Divalproex Sodium20$948

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$331$87,04927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Ft Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →